Heart failure. Heart failure
Conditions
Interventions
Intervention 1: Intervention group: EPA received at a dose of 1000 mg twice a day for 12 weeks in the form of soft gel, taken orally, produced by Taka Pharmed. Intervention 2: Control group: 1000 mg o
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age: 30-75 years old EF = 50% with shortness of breath, fatigue, swelling of the extremities, and other symptoms related to heart failure EF =45-50% with one of the following symptoms: shortness of breath, advanced age, atrial fibrillation, or pulmonary disease NYHA Functional class II & III BMI =25 and = 35 Definitive diagnosis of heart failure based on the patient's clinical symptoms and echocardiographic indicators
Exclusion criteria
Exclusion criteria: Participation in another study within the past three months Change in clinical symptoms within the past week Hospitalization and medication changes within the past 1 month due to worsening of the disease Acute illness (cold, corona and any other viral - bacterial - fungal disease) that causes a change in the patient's inflammatory Taking anticoagulant drugs Taking fish oil supplements within the past 1 month Pregnancy and breastfeeding History of cancer, digestive disorders, advanced renal failure (GFR < 30) or liver failure, malignancies, uncontrolled thyroid disorders, immunodeficiency Serious untreated cardiac disorders such as untreated serious arrhythmias, valvular diseases, extensive coronary artery disease History of major surgeries such as CABG, heart attack or stroke, trauma within the past 6 months People who had ACS within the past three months. Use of corticosteroids, chemotherapy drugs Use of drugs that prolong QT including azithromycin and ciprofloxacin and metoclopramide Inability to perform exercise testing or MWT6 Drug and alcohol addiction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UCP1. Timepoint: First, before the start of the intervention and at the end of the study. Method of measurement: Real-time PCR.;PRDM16. Timepoint: First, before the start of the intervention and at the end of the study. Method of measurement: Real-time PCR.;CIDEA. Timepoint: First, before the start of the intervention and at the end of the study. Method of measurement: Real-time PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Epicardial adipose tissue. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Echocardiography.;Changes in echocardiographic indicators. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Echocardiography.;6-minute walk test (6MWT). Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Stopwatch or timer to measure time.;Weight. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Digital scale.;Waist-to-hip ratio. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Waist circumference (cm) ÷ Hip circumference (cm).;Systolic blood pressure. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Blood pressure measuring device.;Heart Failure Quality of Life Questionnaire. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: Questionnaire and scoring.;Body mass index. Timepoint: At baseline (before the intervention) and at the end of the study. Method of measurement: "Body Mass Index (BMI) is calculated as weight (kg) divided by height squared (m²).". | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein hemmati
Tehran University of Medical Sciences
Outcome results
None listed